Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Tropicamide acts...

    Tropicamide acts faster than Cyclopentolate as a Cycloplegic Agent

    Written by Vinay Singh singh Published On 2018-07-27T19:15:29+05:30  |  Updated On 27 July 2018 7:15 PM IST
    Tropicamide acts faster than Cyclopentolate as a Cycloplegic Agent

    Tropicamide may be considered a viable substitute for cyclopentolate due to its rapid onset of action in controlling cycloplegic refraction(CR), according to the results of a meta-analysis published in the Journal of Optometry.


    CR is a procedure to determine refractive status while the ciliary muscles are temporarily paralyzed with cycloplegic agents. The inadequate cycloplegic effect may shift results in an under-plus or over-minus direction.


    Negareh Yazdani and his associates conducted a meta-analysis to compare the efficacy of cyclopentolate and tropicamide in controlling accommodation during refraction.


    The investigators extracted the data from PubMed, Scopus, Science direct and Ovid databases. The authors included six studies (three randomized controlled trials and three case-control studies)in the meta-analysis.


    The drug of choice should have a rapid onset, appropriate cycloplegic effect, and minimum side effects. Atropine is generally considered for its cycloplegic effects, however, its prolonged blur vision, slow onset and long recovery time have limited its application to very specific conditions.


    Read Also: Refractive Errors – Standard Treatment Guidelines


    Cyclopentolate is a synthetic antimuscarinic cycloplegic agent and is a widely accepted drug as the first choice for patients of all ages which provides excellent short-term cycloplegia. Its effects begin at 25–75min after administration of the drop and recovery appears through 6–24h later.


    Tropicamide, as an alternative, is a synthetic analog of tropic acid and is known as a safe agent for CR. It is characterized by a rapid onset and the cycloplegia effect appears 20–30min after administration. Its recovery appears 6h later.


    The analysis showed that tropicamide was effective in adults and also in those with myopia, with only an insignificant mean refractive difference of 0.175 D more plus in the cyclopentolate group. In children and hyperopes, the difference was statistically greater (0.22 D and 0.25 D, respectively). In addition, determination of refractive error by retinoscopy showed greater plus than by autorefraction.


    The study concluded that tropicamide can produce adequate cycloplegia in certain populations due to its rapid onset of action.

    For reference log on to 10.1016/j.optom.2017.09.001

    CyclopentolatecycloplegicJournal of OptometrymetaanalysisNegareh Yazdanionsetrapidrefractionsynthetictropic acidTropicamide
    Source : With inputs from the Journal of Optometry

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok